

World Journal of *Hepatology*

World J Hepatol 2022 March 27; 14(3): 482-646



REVIEW

- 482 Hepatitis E in immunocompromised individuals
Damiris K, Aghaie Meybodi M, Niazi M, Pyrsopoulos N

MINIREVIEWS

- 495 Small duct primary sclerosing cholangitis: A discrete variant or a bridge to large duct disease, a practical review
Nguyen CM, Kline KT, Stevenson HL, Khan K, Parupudi S
- 504 New progress in understanding roles of nitric oxide during hepatic ischemia-reperfusion injury
Zhang YP, Liu XR, Yang MW, Yang SL, Hong FF
- 516 Renal manifestations of hepatitis E among immunocompetent and solid organ transplant recipients
Kovvuru K, Carbajal N, Pakanati AR, Thongprayoon C, Hansrivijit P, Boonpheng B, Pattharanitima P, Nissaisorakarn V, Cheungpasitporn W, Kanduri SR
- 525 Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
Spera AM

ORIGINAL ARTICLE**Basic Study**

- 535 Fertaric acid amends bisphenol A-induced toxicity, DNA breakdown, and histopathological changes in the liver, kidney, and testis
Korier KMM

Case Control Study

- 551 Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study
Almomani A, Hitawala AA, Kumar P, Alqaisi S, Alshaikh D, Alkhayyat M, Asaad I

Retrospective Cohort Study

- 559 Standards of liver cirrhosis care in Central Australia
Raja SS, Batey RG, Edwards S, Aung HH
- 570 Risk factors and prediction of acute kidney injury after liver transplantation: Logistic regression and artificial neural network approaches
Bredt LC, Peres LAB, Risso M, Barros LCAL

Retrospective Study

- 583 Pediatric liver transplantation outcomes from a single center in Thailand

Prachuaphunyachart S, Sintusek P, Tubjareon C, Chaijitraruch N, Sanpavat A, Phewplung T, Wanawongsawad P, Intrarakamhang AL, Chongsrisawat V

Observational Study

- 592 Predictors of Mortality at 28-days in Infection associated Acute Kidney Injury in Cirrhosis

Gupta T, Ranga N, Goyal SK

- 602 Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy

Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB

- 612 Interrelationship between physical activity and depression in nonalcoholic fatty liver disease

Weinstein AA, De Avila L, Kannan S, Paik JM, Golabi P, Gerber LH, Younossi ZM

- 623 Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma

Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM

Randomized Clinical Trial

- 634 Effect of a specific *Escherichia coli* Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment

Manzhali E, Moyseyenko V, Kondratiuk V, Molochek N, Falalyeyeva T, Kobyliak N

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Rostyslav Bubnov, MD, PhD, LLB, Senior researcher in The Interferon Department of Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine; Medical doctor in The Center of Ultrasound Diagnostics and Interventional Sonography, Clinical Hospital "Pheophania" of Administration of President of Ukraine, Kyiv 03157, Ukraine. rostbubnov@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2021 edition of Journal Citation Reports® cites the 2020 Journal Citation Indicator (JCI) for *WJH* as 0.61. The *WJH*'s CiteScore for 2020 is 5.6 and Scopus CiteScore rank 2020: Hepatology is 24/62.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Rui-Rui Wu, Production Department Director: Xiang Li, Editorial Office Director: Xiang Li.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Nikolaos Pylsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

March 27, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review

Anna Maria Spera

Specialty type: Infectious diseases

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

P-Reviewer: Negro F, Sira AM

Received: November 25, 2021

Peer-review started: November 25, 2021

First decision: December 27, 2021

Revised: January 11, 2022

Accepted: February 15, 2022

Article in press: February 15, 2022

Published online: March 27, 2022



Anna Maria Spera, Infectious Disease Unit, University Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona, Salerno 84131, Italy

Corresponding author: Anna Maria Spera, MD, PhD, Doctor, Infectious Disease Unit, University Hospital OO RR San Giovanni di Dio e Ruggi d'Aragona, Largo Ippocrate, Salerno 84131, Italy. annamariaspera@hotmail.it

Abstract

With a globally estimated 58 million people affected by, chronic hepatitis C virus (HCV) infection still represents a hard challenge for scientific community. A chronic course can occur among patients with a weak innate and adaptive response with cirrhosis and malignancies as main consequences. Oncologic patients undergoing chemotherapy represent a special immunocompromised population predisposed to HCV reactivation (HCVr) with undesirable changes in cancer treatment and outcome. Aim of the study highlight the possibility of HCVr in oncologic population eligible to chemotherapy and its threatening consequences on cancer treatment; underline the importance of HCV screening before oncologic therapy and the utility of direct acting antivirals (DAAs). A comprehensive overview of scientific literature has been made. Terms searched in PubMed were: "HCV reactivation in oncologic setting" "HCV screening", "second generation DAAs". Pharmacokinetic and Pharmacodynamics characteristics of DAAs are reported, along with drug - drug interactions among chemotherapeutic drug classes regimens and DAAs. Clinical trials conducted among oncologic adults with HCV infection eligible to both chemotherapy and DAAs were analyzed. Viral eradication with DAAs in oncologic patients affected by HCV infection is safe and helps liver recovery, allowing the initiation of cancer treatment not compromising its course and success.

Key Words: Hepatitis C Virus; Direct acting antivirals; Drug interactions; Pharmacodynamic; Pharmacokinetic; Pre-emptive therapy

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Chronic hepatitis C virus (HCV) infection is a hard clinical challenge, especially regarding oncologic patients eligible to chemotherapy. HCV reactivation in this setting of population is due to iatrogenic immunosuppression and can impair cancer treatment and outcome. Several specialists still do not prescribe direct acting antivirals to oncologic patients affected by HCV infection, because no univocal guidelines on HCV treatment in oncologic setting are available. The review highlights the importance of screening HCV infection before starting oncologic treatment, the safety of direct acting antivirals treatment under chemotherapy and the utility of treating HCV infection in oncologic setting no compromising chemotherapy course and success.

Citation: Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. *World J Hepatol* 2022; 14(3): 525-534

URL: <https://www.wjgnet.com/1948-5182/full/v14/i3/525.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v14.i3.525>

INTRODUCTION

Hepatitis C is a viral infection due to a single-stranded RNA enveloped virus, with a mainly hepatic tropism. Eight genotypes of hepatitis C virus (HCV) along with several different subtypes have been identified[1,2]. Since its discovery, in 1989, 184 million patients with hepatitis C have been reported worldwide[3], and 40% of hepatic transplantations performed until 2009 were due to HCV-based liver cirrhosis[1]. According to the World Health Organization, an estimated 58 million people worldwide live with chronic HCV infection in 2021, with approximately 1.5 million new infections occurring per year, and approximately 400000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma, in 2019[3].

BIOLOGICAL COURSE OF HCV INFECTION

The interplay between viral replication and a patient's immune response determines the biological course of HCV infection[4], considering that viral immune tropism secondary to hepatocyteinfection activates the innate and adaptive immune systems.

The typical outcome of primary infection in immunocompetent subjects is a self-limited illness with spontaneous resolution after an acute phase, characterized by host-protective antibody production. Otherwise, a chronic course of hepatitis has been often described in exposed patients, with weak innate and adaptive immune responses determining an insufficient reduction in viral load, despite concomitant liver function recovery[4]. Consequences of chronicity are cirrhosis and hepatocarcinogenesis[5,6], along with haematologic malignancies, including B cell non-Hodgkin's lymphoma[7], intrahepatic cholangiocarcinoma and other solid tumours, such as head and neck, colorectal, renal, and pancreatic cancers[7,8,9]. Any kind of immune central reconstitution after immunosuppressive medication can trigger viral reactivation in this chronic setting of HCV, with diversified clinical manifestations ranging from asymptomatic flares of transaminases to severe liver damage[4].

Approximately two weeks before hepatitis flares, an increase in viral RNA often occurs[4]. Hepatitis C reactivation is therefore defined by an increase in HCV-RNA > 1 Log IU/mL over baseline, while the detection of anti-HCV antibodies cannot help in distinguishing between acute and chronic infection but can determine only the occurrence of an infection[10]. Early identification of HCV infection and/or its reactivation can be merely ensured only by liver function testing and anti-HCV and viral load level surveillance.

HCV REACTIVATION IN AN ONCOLOGIC SETTING

According to Rung Li *et al*[11], HCV reactivation (HCVr) in an oncologic setting is promoted by immunosuppression due to chemotherapy, often resulting in deleterious changes in the cancer treatment plan and its outcomes. HCVr prevalence rates in cancer patients receiving chemotherapy range from 1.5% to 32% worldwide[12]. Although less fearful than HBV reactivation, HCVr is challenging for oncologists and HCV treating physicians, who often avoid administering antiviral treatment to patients under chemotherapy because of a lack of data about the safety of this treatment combination[12,10]. The multicentre, prospective cohort study performed by Ramsey and colleagues[13] among more than 5000 new oncologic patients found an observed infection rate of 2.4% (95%CI: 1.9% to 3.0%) for HCV, with a substantial proportion of patients being unaware of their viral status at the time

of cancer diagnosis (31%) and having no identifiable related risk factors (32.4%). Finally, according to this cohort study, therapeutic decisions were changed in 8% of patients because of their viral status[4, 13]. In an observational study conducted at MD Anderson Cancer Center, an HCVr rate of 23% was estimated among patients with cancer (36% in haematologic and 10% in solid tumour settings), with a more frequent recurrence in patients with prolonged lymphopenia (median 95 vs 22 d, $P < 0.001$) and in patients receiving rituximab (44% vs 9%), bendamustine (22% vs 0%), high-dose steroids (57% vs 21%) and purine analogues (22% vs 5%). The study also showed an unanticipated discontinuation or dose reduction of chemotherapy for 26% (6 of 23) of oncologic patients with HCVr[4]. In both studies, it was concluded that the early identification and treatment of chronic HCV hepatitis prevent HCVr after iatrogenic immunodepression and the remodulation of chemotherapy itself. Thus, screening for HCV infection before cancer treatment appears to be useful and advisable. Figure 1 shows an HCV screening recommendation flowchart for oncologic patients eligible for chemotherapy.

HCV INFECTION THERAPEUTIC STRATEGIES

HCV infection therapeutic strategies have changed over time[2]. The first therapeutic combination employed against HCV infection in 1990 was based on interferon (IFN) plus ribavirin, which was associated with suboptimal response rates and short- and long-term toxicity even related to drug-to-drug interactions with other medications taken[14]. Moreover, because of intrinsic contraindications for each element of the compound, patients with unbalanced mood unbalanced or anaemia were excluded from the treatment[14]. The first direct-acting antivirals (DAAs), boceprevir and telaprevir, were approved in 2011; since then, the HCV cure rates have markedly improved, and they have been added to the classic dual therapy represented by IFN + ribavirin[15]. After the introduction of the combined regimens based on glecaprevir/pibrentasvir [Glecaprevir (GLE)/Pibrentasvir (PIB)], sofosbuvir/velpatasvir [(SOF)/Velpatasvir (VEL)] with, or without voxilaprevir (VOX), and elbasvir/grazoprevir [Elbasvir (EBR)/Grazoprevir (GZR)], summarized in Table 1, the majority of chronic HCV-infected patients have been treated since 2015, achieving sustained virologic response (SVR)[16-20].

PHARMACOKINETIC CHARACTERISTICS OF CURRENTLY USED DAAS

In relation to the pharmacokinetic characteristics of currently used DAAs, the time to maximal plasma concentration (t_{max}), maximal plasma concentration (c_{max}), area under the concentration time curve (AUC) and minimal plasma concentration (c_{min}) are considered with regard to absorption, while the apparent volume of distribution (V_d/L) and percentage of protein binding are considered in relation to distribution. Metabolism is described in terms of the type of substrate elicited by DAAs and excretion as the elimination half-life (T_{1/2})[1].

The pharmacokinetic characteristics of currently used DAAs are summarized in Table 2.

EBR/ GZR

Absorption: EBR is a substrate of P-gp, with a median t_{max} of 3 h and a range of 3-6 h. The bioavailability is estimated approximately 32%. Absorption (AUC 11% and C_{max} 15%) can be decreased by a high-fat meal (900 kcal; 500 kcal fat). GZR acts as a substrate for P-gp and has a median t_{max} of 2 h with a range of 0.5-3 h. The absolute bioavailability varies from 15 to 27% after a single dose and from 20 to 40% after multiple doses. Absorption (AUC 50% and C_{max} 108%) can be increased by a high-fat meal (900 kcal; 500 kcal fat). HCV-infected patients have increased exposure (approximately 2-fold) compared with healthy individuals. Steady state is reached at approximately the sixth day of administration[21, 22].

Distribution: EBR and GZR are highly bound to albumin for > 99.9% and to α 1-acid glycoprotein for > 98.8%[23,24]. The estimated V_d/L values for EBR and GZR are 680 and 1250 L, respectively. The hepatic transporter OATP1B1/3 actively transports GZR[25]. EBR inhibits P-gp. EBR and GZR inhibit BCRP[21, 22].

Metabolism: EBR and GZR are metabolized by CYP3A4, but no circulating metabolites can be found in plasma. CYP3A4 is weakly inhibited by GZR[21,22].

Excretion: EBR and GZR are excreted mainly by liver; more than 99% of the excreted dose can be found in faeces. The apparent t_{1/2} of EBR and GZR is 24 and 31 h[21,22].

SOF/VEL

Absorption: The SOF C_{max} after administration is 0.5-1 h. The AUC_∞ of SOF can be increased by 60% and 78% by a moderate- and high-fat meal, respectively. However, the SOF C_{max} is not affected by food [23,24]. The VEL median t_{max} is estimated around 3 h, while the AUC and C_{max} values are lower in healthy volunteers (41% and 37%), when compared to those of HCV-infected subjects. The AUC of VEL

Table 1 Currently used direct aging antiviral characteristics

Trade name	Compound	Year of FDA/EMA approval	Mechanism of action	Pharmaceutical form	Dose	Genotypes
Zepatier	Elbasvir/grazoprevir	2016	NS5A inhibitor/protease inhibitor	Film-coated tablet	50 mg/100 mg qd	1a, 1b, 4
Eplusa	Sofosbuvir/velpatasvir	2016	NS5B inhibitor/NS5A inhibitor	Film-coated tablet	400 mg/100 mg	Pangenotypic
Maviret	Glecaprevir/pibrentasvir	2017	Protease inhibitor/NS5A inhibitor	Film-coated tablet	100 mg/40 mg qd	Pangenotypic
Vosevi	Sofosbuvir/velpatasvir/voxilaprevir	2018/2017	NS5B inhibitor/NS5A inhibitor/protease inhibitor	Film-coated tablet	400 mg/100 mg/100 mg	Pangenotypic

DAA: Direct aging antiviral; FDA: Food and drug administration; EMA: European Medicines Agency.

Table 2 Pharmacokinetics of currently used direct aging antivirals

DAAs		Absorption				Distribution		Metabolism	Excretion
Tradename	Compound	<i>T_{max}</i> (h)	<i>C_{max}</i> (ng/mL)	<i>C_{min}</i> (ng/mL)	AUC (ng·h/mL)	Vd/F	Protein binding (%)	Substrate of	T _{1/2} (h)
Zepatier	Elbasvir	3	121	48.4	1920	680	> 99.9	P-gp	31
	Grazoprevir	2	165	18.0	1420	1250	> 98.8	P-gp	24
Eplusa	Sofosbuvir	0.5-1/3	566/868	NR	1260/13970	NR	61-65 minim	P-gp and BCRP	0.5/25
	Velpatasvir	4	311	NR	2970	NR	> 99.5	P-gp, OATP1B, and BCRP	15
Maviret	Glecaprevir	5.0	597	NR	4800	NR	97	P-gp	6-9
	Pibrentasvir	5.0	110	NR	1430	NR	> 99.9	P-gp	23-29
Vosevi	Sofosbuvir	2/4	678/744	NR	1665/12,834	NR	61-65 minim	P-gp and BCRP	0.5/29
	Velpatasvir	4	311	NR	4041	NR	> 99	P-gp, OATP1B1/3, and BCRP	17
	Voxilaprevir	4	192	47	2577	NR	> 99	P-gp and BCRP	33

DAAs: Direct aging antivirals; NR: Data not reported and/or available; T_{1/2}: Elimination half time.

can be increased after a moderate- (600 kcal; 30% fat) and high-fat (800 kcal; 50% fat) meals, while the *C_{max}* increases by only 34% and 5%, respectively. The solubility of VEL is pH-dependent: In fact the increase of pH determines a reduction in solubility and absorption[23,24].

Distribution: Circulation proteins highly protein bind VEL (> 99.5%), regardless of the concentration range 0.09-1.8 µg/mL of the drug. SOF acts as a substrate of BCRP and P-gp. VEL acts as a substrate of BCRP, P-gp and OATP1B[25,26]. Plasma proteins that are not dose-dependent (1-20 µg/mL) bind SOF at 61%-65%[23,24].


Metabolism: VEL is metabolized by CYP2B6, CYP2C8, and CYP3A4, but > 98% of the parent drug can be found in the blood after a single dose. VEL inhibits P-gp, BCRP, and OATP1B1/3[23,24]. Refers to the SOF/VEL/VOX paragraph for SOF metabolism.

Excretion: The clearance of VEL is mainly hepatic, VEL is retrieved in faeces for > 94% and in urine for 0.4%. The t_{1/2} of VEL is approximately 15 h[25,26]. SOF is mainly excreted by kidneys (80%) as GS-331007 (78%). The t_{1/2} of SOF is 0.5 h, while the t_{1/2} of GS-331007 is 25 h[23,24].

GLE/PIB

Absorption: The *t_{max}* of GLE/PIB is about 5 h. Fat meals (moderate and high) can increase the absorption of GLE/PIB: The exposure of GLE after a meal is increased 83%-163% and the exposure of PIB is increased 40%-53%. Both drugs are P-gp substrates[25,26].

Distribution: Plasma proteins highly bind 97.5% to GLE and > 99.9% to PIB, both of drugs are actively



DOI: 10.4254/wjh.v14.i3.525 Copyright The Author(s) 2022.

Figure 1 Hepatitis C virus screening flowchart for oncologic patients eligible for chemotherapy. HCV: Hepatitis C virus; DAA: Direct acting antiviral.

transported by BCRP. GLE constitutes also a substrate of OATP1B1/3[25,26].

Metabolism: GLE is metabolized by CYP3A4, and PIB does not undergo biotransformation[25,26].

Excretion: GLE is primarily excreted by the liver; in fact, 92.1% of a radioactive dose is retrieved in faeces. The $t_{1/2}$ is 6-9 h at steady state. PIB is also primarily found in stool (96.6%), with a $t_{1/2}$ of 23-29 h [25,26].

SOF/VEL/VOX

Absorption: The C_{max} of VOX, VEL, and a major metabolite of SOF, namely, GS-331007 is reached after approximately 4 h; the C_{max} of SOF is reached after 2 h. The AUC and C_{max} of VEL are 41% and 39% decreased in patients, respectively, while the AUC and C_{max} of VOX are both elevated by 260% when comparing HCV-infected individuals and healthy volunteers[27,28]. The AUC_{∞} and C_{max} of SOF increase from 64 to 114% and 9% to 76%, respectively, after a meal. The C_{max} of GS-331007 after a meal decreases (19%-35%). The AUC_{∞} and C_{max} of VEL increase (40%-166% and 37%-187%, respectively). The AUC of VOX increases from 112% to 435%, while the C_{max} of VOX increases from 147% to 680% [27,28].

Distribution: Plasma proteins highly bind to SOF, VEL, and VOX (61%-65%, > 99%, and > 99%, respectively), with a concentration independent pharmacokinetics (ranging from 1 to 20 and 0.09 to 1.8 $\mu\text{g}/\text{mL}$, respectively) for SOF and VEL. SOF acts as a substrate of P-gp and BCRP, while VEL acts as a substrate of P-gp, OATP1B1/3, and BCRP. Finally, VOX acts as a substrate of P-gp and BCRP[27,28].

Metabolism: VOX is a substrate of CYP3A4. VOX is an inhibitor of P-gp, BCRP, and OATP1B1/3[27,28]. The metabolism of SOF and VEL is reported in the paragraph on SOF/VEL combination therapy

above.

Excretion: SOF is excreted by the kidneys (80%), mainly in the form of GS-331007 (78%). The t_{1/2} of SOF is 0.5 h and the t_{1/2} of GS-331007 is 29 h[28,29]. The clearance of VEL is mainly hepatic. The t_{1/2} of VEL is approximately 17 h (27). The excretion is mainly biliary[27,28].

PHARMACODYNAMICS OF CURRENTLY USED DAAS

Intended as the balance between the effect (reduction of HCV-RNA under therapy) and toxicity (adverse effects), the pharmacodynamics of currently used DAAs consist of the duration of therapy, safety profile and estimated adverse effects.

EBR/GZR is efficacious for subjects affected by genotypes 1 and 4 HCV infection treated for 12 wk. EBR/GZR is approved for patients with renal insufficiency and compensated cirrhosis. This combination is approved in the fixed dose combination of 50 mg/100 mg once daily. The favourable safety profile with low discontinuation rates (< 5%) makes this compound suitable for HCV-infected patients with genotypes 1 and 4. The most frequent adverse effects are fatigue, headache, asthenia, nausea, rash, and an increase in ALT/AST and ALP[1,21].

SOF/VEL combination for 12 wk is valid in HCV pangenotypic patients treatment-experienced and/or treatment-naïve. Mild described adverse events are headache, fatigue, nausea and insomnia. Combination therapy with ribavirin leads to anaemia in over 10% of patients[1,24].

GLE/PIB is a pangenotypic regimen that is highly effective when administered for 8 to 12 wk once daily at doses of 100 mg/40 mg. Naïve and experienced patients with or without cirrhosis can be treated with this compound, which has a mild toxicity profile, in which headache, fatigue, nasopharyngitis and nausea can arise[1,25].

Finally, the pangenotypic highly effective SOF/VEL/VOX combination is licenced for patients who fail to respond to IFN/riba and DAAs and those with or without compensated cirrhosis. The adverse effects described are headache, diarrhoea, fatigue, nausea and constipation[1,27].

The pharmacodynamic properties of currently used DAAs are summarized in [Table 3](#).

DRUG TO DRUG INTERACTIONS

Drug-drug interactions are challenging in the course of cotreatment with chemo-therapy and DAAs because most of these compounds are substrates and inhibitors of drug transporters and CYP enzymes [7]. Consulting the HEP drug interaction website can be extremely useful for clinical decision-making [29]: A report listing the summaries of potential interactions (*i.e.*, "red", "amber" and "yellow" classifications) for the drugs considered can be downloaded to guide the choice on a case-by-case basis. Potential interactions between currently used DAAs and the following drug classes of chemotherapy regimens are reported in this review: Platinum-containing agents (cisplatin, carboplatin, oxaliplatin), folate antagonists (methotrexate, pemetrexed), pyrimidine compounds (fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine), purine analogues (mercaptopurine, fludarabine, cladribine, clofarabine), alkylating agents (cyclophosphamide, ifosfamide, melphalan, bendamustine, busulfan), anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin, bleomycin), topoisomerases (topotecan, etoposide, irinotecan), cytidine analogues (azacytidine, decitabine), immunosuppressants (tacrolimus, cyclosporine), immunomodulatory drugs (lenalidomide, thalidomide), mitotic inhibitors (paclitaxel, docetaxel, vinblastine, vincristine), hormonal therapies (tamoxifen), targeted therapies other than rituximab (*e.g.*, cetuximab, bortezomib, alemtuzumab). Interactions between DAAs and the main oncologic therapeutic categories considered in this review are summarized in [Table 4](#).

According to the Liverpool HEP chart, drugs that absolutely should not be coadministered (RED interactions) are as follows: Elbasvir/grazoprevir + immunosuppressants (cyclosporine): Concomitant use of elbasvir/grazoprevir with OATP1B inhibitors, such as cyclosporine, is contraindicated. The coadministration of multiple doses of elbasvir/grazoprevir and a single dose of cyclosporin increases the grazoprevir AUC by 15-fold. The risk of ALT elevations may be increased due to the significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition[29].

Sofosbuvir/velpatasvir/voxilaprevir + folate antagonists (methotrexate): Coadministration has not been studied but would not be recommended due to increased exposure to methotrexate due to BCRP inhibition by voxilaprevir[29]. Sofosbuvir/velpatasvir/voxilaprevir + immunosuppressants (cyclosporine): Coadministration has been studied with sofosbuvir, velpatasvir or voxilaprevir, and coadministration with sofosbuvir/velpatasvir/voxilaprevir is not recommended. Concentrations of voxilaprevir increased by 19.0-fold due to OATP1B1 inhibition by cyclosporine. The safety of this increase has not been established[29].

According to the Liverpool HEP chart, potential clinically significant interactions-likely to require additional monitoring and an alteration of drug dosage or the timing of administration (AMBER

Table 3 Pharmacodynamics of currently used direct acting antivirals

Trade name	Compound	Efficacy	Toxicity
Zepatier	Elbasvir/grazoprevir	Effective regimen used for 12 wk against HCV genotype 1 and 4. Approved for patients with renal insufficiency and compensated cirrhosis. Fixed dose combination of 50 mg/100 mg once daily. Favourable safety profile with low discontinuation rates (< 5%)	Fatigue, headache, asthenia, nausea, rash, ALT/AST and ALP increase
Eplclusa	Sofosbuvir/velpatasvir	Treatment for 12 wk highly effective in both treatment-experienced and treatment-naïve HCV pangenotypic patients	Fatigue, headache, nausea and insomnia. Combination therapy with ribavirin led to anaemia in over 10% of patients
Maviret	Glecaprevir/pibrentasvir	Pangenotypic highly effective regimen. Administered for 8 to 12 wk once daily at doses of 100 mg/40 mg. Naïve and experienced patients with or without cirrhosis	Headache, fatigue, nasopharyngitis and nausea
Vosevi	Sofosbuvir/velpatasvir/voxilaprevir	Pangenotypic, highly effective, licenced for patients in whom IFN/riba and DAAs failed	Headache, diarrhoea, fatigue, nausea and constipation

ALT: Alanine transaminase; AST: Aspartate transaminase; DAAs: Direct acting antivirals; HCV: Hepatitis C virus; IFN: Interferon.

Table 4 Chemotherapy drug classes employed

Chemotherapy drug classes	Examples
Platinum-containing agents	(Cisplatin, carboplatin, oxaliplatin)
Folate antagonists	(Methotrexate, pemetrexed)
Pyrimidine compounds	(Fluorouracil, capecitabine, cytarabine, gemcitabine, decitabine)
Purine analogues	(Mercaptopurine, fludarabine, cladribine, clofarabine)
Alkylating agents	(Cyclophosphamide, ifosfamide, melphalan, bendamustine, busulfan)
Anthracyclines	(Daunorubicin, doxorubicin, epirubicin, idarubicin, bleomycin)
Topoisomerases	(Topotecan, etoposide, irinotecan)
Cytidine analogues	(Azacytidine, decitabine)
Immunosuppressants	(Tacrolimus, cyclosporine)
Immunomodulatory drugs	(lenalidomide, thalidomide)
Mitotic inhibitors	(Paclitaxel, docetaxel, vinblastine, vincristine)
Hormonal therapies	(Tamoxifen)
Targeted therapies other than rituximab	(<i>e.g.</i> , cetuximab, bortezomib, alemtuzumab)

interactions)-are described among the following: Elbasvir/grazoprevir + folate antagonists (methotrexate): Coadministration has not been studied. Methotrexate is a substrate of BCRP, and concentrations could increase due to inhibition by elbasvir/grazoprevir. No a priori dose alteration is recommended, but patients should be closely monitored[29]. Sofosbuvir/velpatasvir + folate antagonists (methotrexate): Coadministration has not been studied. Methotrexate is a substrate of BCRP, and concentrations may increase due to inhibition by sofosbuvir/velpatasvir. Although no a priori dose alteration is required, close monitoring is recommended[29]. Glecaprevir/pibrentasvir + immunosuppressants (cyclosporine): Concomitant use of glecaprevir/pibrentasvir with cyclosporine requires close monitoring of doses, as concentrations of glecaprevir/pibrentasvir may increase due to the inhibition of OATP1B. The coadministration of gleca-previr/pibrentasvir and cyclosporine (100 mg) increased glecaprevir/pibrentasvir concentrations within acceptable parameters (glecaprevir C_{max}, AUC and C_{min} by 30%, 37% and 34%, respectively; no change in pibrentasvir C_{max} and AUC, but C_{min} increased by 26%). However, at higher doses of cyclosporine (400 mg), glecaprevir concentrations increased significantly (C_{max} 4.51-fold, AUC 5.08-fold). Glecaprevir/pibrentasvir is not recommended for use in patients requiring stable cyclosporine doses at 100 mg/d[29]. Glecaprevir/pibrentasvir + anthracyclines (doxorubicin): Coadministration has not been studied. Doxorubicin is metabolized by CYP enzymes and is a substrate for P-gp. Since gleca-previr/pibrentasvir inhibits P-gp and is a mild inhibitor of CYP3A4, there is the potential for increased doxorubicin exposure, and a clinically significant interaction has to be considered[29]. Glecaprevir/pibrentasvir + folate antagonists

(methotrexate): Coadministration has not been studied. Methotrexate is a substrate of BCRP, and concentrations could increase due to the inhibition of BCRP by glecaprevir/pibrentasvir. Patients should be closely monitored for methotrexate-associated toxicities[29]. Glecaprevir/pibrentasvir + immunosuppressants (tacrolimus): The coadministration of glecaprevir/pibrentasvir with systemic tacrolimus (1 mg single dose) increased tacrolimus Cmax and AUC by 1.5-fold and 1.45-fold, respectively. There was no change in the Cmax, AUC or Cmin of glecaprevir or pibrentasvir. As tacrolimus is a narrow therapeutic index drug, it should be used with caution. Therapeutic blood monitoring should be performed[29]. Sofos-buvir/velpatasvir/voxilaprevir + immunosuppressant (tacrolimus): Coadministration with sofosbuvir/velpatasvir/voxilaprevir has not been studied. No clinically significant drug interactions were observed with sofosbuvir and tacrolimus. The coadministration of tacrolimus (5 mg single dose) and sofosbuvir (400 mg single dose, $n = 16$) decreased tacrolimus Cmax by 27% and increased AUC by 9%; sofosbuvir Cmax decreased by 3% but AUC increased by 13%. No effect of velpatasvir or voxilaprevir is expected. However, in the absence of data, the monitoring of tacrolimus concentrations should be considered[29]. Elbasvir/grazoprevir + mitotic inhibitors (paclitaxel): Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Grazoprevir is a weak inhibitor of CYP3A4 and could potentially increase paclitaxel exposure. Paclitaxel-induced toxicity should be monitored[29]. Glecaprevir/pibrentasvir + mitotic inhibitors (paclitaxel): Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Glecaprevir is a weak inhibitor of CYP3A4 and could potentially increase paclitaxel exposure. Paclitaxel-induced toxicity should be monitored[29]. Elbasvir/grazoprevir + immunosuppressants (tacrolimus): The coadministration of elbasvir/grazoprevir with systemic tacrolimus increased tacrolimus AUC by 43% (due to weak inhibition of CYP3A4 by grazoprevir) but had no effect on the concentrations of grazoprevir and elbasvir. Frequent monitoring of tacrolimus whole-blood concentrations, changes in renal function, and tacrolimus-associated adverse events upon the initiation of coadministration is recommended[29].

According to the Liverpool HEP chart, potentially weak interactions-for which additional action/monitoring or dosage adjustment is unlikely to be required (YELLOW interactions)-are described among the following: Sofosbuvir/velpatasvir + hormonal therapies (tamoxifen): Coadministration has not been studied. Tamoxifen is mainly metabolized by CYP3A4 and CYP3A5, which are not affected by sofosbuvir/velpatasvir. However, tamoxifen induces CYP3A4 and could potentially decrease the concentrations of velpatasvir, although to a moderate extent. Coadministration with food is suggested if tamoxifen is coadministered with sofosbuvir/velpatasvir as this increases exposure to velpatasvir[29]. Sofosbuvir/ velpatasvir/voxilaprevir + hormonal therapies (tamoxifen): Coadministration has not been studied. Tamoxifen is mainly metabolized by CYP3A4 and CYP3A5, which are not affected by sofosbuvir/velpatasvir/voxilaprevir. However, tamoxifen induces CYP3A4 and could potentially decrease the concentrations of velpatasvir and voxilaprevir, although to a moderate extent. Coadministration with food is suggested if tamoxifen is coadministered with sofosbuvir/ velpatasvir/voxilaprevir as this increases exposure to velpatasvir and voxilaprevir[29].

Some comedications with a green classification may require dose adjustment due to hepatic impairment.

MANAGEMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH CANCER

HCV-infected oncologic patients represent a special population needing guided treatment[12]: The updated guidelines provided by the AASL and IDSA[4] for the first time address treatment in this setting, supporting that the virologic and hepatic benefits of DAA treatment in oncologic patients with HCV infection overcome the risk of no treatment[7,30,31]. In fact, the quick eradication of chronic HCV infection prior to cancer therapy helps liver recovery, normalizes liver enzymes and avoids potentially decompensating hepatitis flares; in other words, it allows the initiation of cancer treatment that could be hampered by persistent elevated ALT levels due to HCV virus infection[12]. The eradication of HCV in oncologic patients can also diminish the risk of HCVr, allow patients to participate in experimental oncologic clinical trials based on new drug strategies against cancer, reduce the risk of the development of HCV-associated cancers[4], minimize drug-induced hepatotoxicity and avoid detrimental dose reduction.

DAA-based therapy can also promote liver disease progression[12]. In clinical practice, the temporary suspension of cancer treatment during DAA-based therapy has often been observed to avoid overlapping toxicities and DDIs. However, the present review proves that when cancer treatment cannot be interrupted, currently used DAAs can be simultaneously administered under close comonitoring by oncologists and hepatologists, especially during the first month of this dual therapy, since serious observed adverse events most usually appear within the first 2-4 wk of concomitant treatment.

CONCLUSION

Economides *et al*[12] stated that DAA therapy in cancer patients was efficacious and durable in terms of SVR, and few drug-drug interactions were observed. Otherwise, prospective data on HCV in oncologic patients remain limited.

This review, in the absence of current specific available guidelines for the use of DAA therapy in HCV-infected cancer patients, tried to clarify that treatment with DAAs for oncologic patients undergoing chemotherapy affected by HCV infection is safe and favourably impacts oncologic outcomes.

Finally, given that cancer treatment can negatively impact untreated chronic HCV-related liver disease, it appears clear that pre-emptive antiviral therapy in the oncologic setting is necessary to pursue chemotherapy without risking the progression of viral liver disease.

FOOTNOTES

Author contributions: Spera AM studied conception and design; data collection; analysis and interpretation of results; draft manuscript preparation; Spera AM finally reviewed the results and approved the final version of the manuscript.

Conflict-of-interest statement: The authors declare that they have no competing interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Anna Maria Spera 0000-0003-1292-3040.

S-Editor: Liu JH

L-Editor: A

P-Editor: Liu JH

REFERENCES

- 1 **Smolders EJ**, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. *Clin Pharmacokinet* 2019; **58**: 1237-1263 [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0]
- 2 **Gao LH**, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. *Int J Gen Med* 2021; **14**: 289-301 [PMID: 33536776 DOI: 10.2147/IJGM.S283910]
- 3 **Hepatitis C – World Health Organization**. Accessed 16 Nov 2021. Available from: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>
- 4 **Ziogas DC**, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. *J Immunother Cancer* 2020; **8** [PMID: 33067316 DOI: 10.1136/jitc-2020-000943]
- 5 **Hwang JP**, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Torres HA, Bailey HH. Oncologic Implications of Chronic Hepatitis C Virus Infection. *J Oncol Pract* 2019; **15**: 629-637 [PMID: 31825756 DOI: 10.1200/JOP.19.00370]
- 6 **Perz JF**, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; **45**: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
- 7 **Torres HA**, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. *CA Cancer J Clin* 2017; **67**: 411-431 [PMID: 28683174 DOI: 10.3322/caac.21403]
- 8 **Mahale P**, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ, Torres HA. Association Between Hepatitis C Virus and Head and Neck Cancers. *J Natl Cancer Inst* 2016; **108** [PMID: 27075854 DOI: 10.1093/jnci/djw035]
- 9 **Balakrishnan M**, Glover MT, Kanwal F. Hepatitis C and Risk of Nonhepatic Malignancies. *Clin Liver Dis* 2017; **21**: 543-554 [PMID: 28689592 DOI: 10.1016/j.cld.2017.03.009]
- 10 **Torres HA**, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. *Hepatology* 2018; **67**: 36-47 [PMID: 28653760 DOI: 10.1002/hep.29344]
- 11 **Li YR**, Hu TH, Chen WC, Hsu PI, Chen HC. Screening and prevention of hepatitis C virus reactivation during chemotherapy. *World J Gastroenterol* 2021; **27**: 5181-5188 [PMID: 34497443 DOI: 10.3748/wjg.v27.i31.5181]
- 12 **Economides MP**, Mahale P, Kyvernitikis A, Turturro F, Kantarjian H, Naing A, Hosry J, Shigle TL, Kaseb A, Torres HA.

- Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. *Aliment Pharmacol Ther* 2016; **44**: 1235-1241 [PMID: 27730654 DOI: 10.1111/apt.13825]
- 13 **Ramsey SD**, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. *JAMA Oncol* 2019; **5**: 497-505 [PMID: 30653226 DOI: 10.1001/jamaoncol.2018.6437]
 - 14 **Ghany MG**, Liang TJ. Current and future therapies for hepatitis C virus infection. *N Engl J Med* 2013; **369**: 679-680 [PMID: 23944318 DOI: 10.1056/NEJMc1307589]
 - 15 **Strader DB**, Seeff LB. A brief history of the treatment of viral hepatitis C. *Clin Liver Dis (Hoboken)* 2012; **1**: 6-11 [PMID: 31186837 DOI: 10.1002/cld.1]
 - 16 **Smith BD**, Jorgensen C, Zibbell JE, Beckett GA. Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. *Clin Infect Dis* 2012; **55** Suppl 1: S49-S53 [PMID: 22715214 DOI: 10.1093/cid/cis363]
 - 17 **Garrison KL**, German P, Mogalian E, Mathias A. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection. *Drug Metab Dispos* 2018; **46**: 1212-1225 [PMID: 29695614 DOI: 10.1124/dmd.117.079038]
 - 18 **Chahine EB**, Kelley D, Childs-Kean LM. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. *Ann Pharmacother* 2018; **52**: 352-363 [PMID: 29115151 DOI: 10.1177/1060028017741508]
 - 19 **Karaoui LR**, Mansour H, Chahine EB. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C. *Am J Health Syst Pharm* 2017; **74**: 1533-1540 [PMID: 28947524 DOI: 10.2146/ajhp160558]
 - 20 **Yao Y**, Yue M, Wang J, Chen H, Liu M, Zang F, Li J, Zhang Y, Huang P, Yu R. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis. *Can J Gastroenterol Hepatol* 2017; **2017**: 8186275 [PMID: 28164081 DOI: 10.1155/2017/8186275]
 - 21 **European Medicines Agency**. Summary of product characteristics: Zepatier. 2019. Accessed 16 Nov 2021. Available from: https://www.ema.europa.eu/documents/product-information/zepatier-epar-product-information_en.pdf
 - 22 **US Food and Drug Administration**. Highlights of prescribing information: Zepatier. 2019. Accessed 16 Nov 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/Label/2017/208261s002Lb1.pdf
 - 23 **European Medicines Agency**. Summary of product characteristics: Eplusa [in Dutch]. 2019. Accessed 16 Nov 2021. Available from: https://www.ema.europa.eu/documents/product-information/eplusa-epar-product-information_nl.pdf
 - 24 **US Food and Drug Administration**. Highlights of prescribing information: Eplusa. 2019. Accessed 16 Nov 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/Label/2017/208341s007Lb1.pdf
 - 25 **European Medicines Agency**. Summary of product characteristics: Maviret 2019. Accessed 16 Nov 2021. Available from: https://www.ema.europa.eu/documents/product-information/maviret-epar-product-information_nl.pdf
 - 26 **US Food and Drug Administration**. Highlights of prescribing information: Maviret. 2019. Accessed 16 Nov 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/Label/2017/209394s000Lb1.pdf
 - 27 **European Medicines Agency**. Summary of product characteristics: Vosevi. 2019. Accessed 16 Nov 2021. Available from: https://www.ema.europa.eu/documents/product-information/vosevi-epar-product-information_en.pdf
 - 28 **US Food and Drug Administration**. Highlights of prescribing information: Vosevi. 2019. Accessed 16 Nov 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/Label/2017/209195s000Lb1.pdf
 - 29 DAAs-chemotherapies drug-drug interactions according to Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. Accessed 16 Nov 2021. Available from: <https://www.hep-druginteractions.org>
 - 30 **Torres HA**, Pundhir P, Mallet V. Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis. *Gastroenterology* 2019; **157**: 909-916 [PMID: 30797794 DOI: 10.1053/j.gastro.2019.01.271]
 - 31 **AASLD-IDSAs**. Hcv guidance: recommendations for testing, managing, and treating hepatitis C. Accessed 16 Nov 2021. Available from: <https://www.Hcvguidelines.Org>



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

